[
  {
    "ts": "2025-12-21T12:31:23+00:00",
    "headline": "Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study",
    "summary": "Fulcrum Therapeutics, Inc. (NASDAQ:FULC) is one of the 12 best multibagger stocks to buy heading into 2026. Following encouraging updates from the ongoing Phase 1b PIONEER study evaluating pociredir in sickle cell disease, analyst sentiment around Fulcrum Therapeutics, Inc. (NASDAQ:FULC) appears to be growing. As of December 18, 2025, 80% of analysts are bullish on […]",
    "url": "https://finance.yahoo.com/news/bullish-analyst-sentiment-fulcrum-therapeutics-123123949.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "9e9aa5fe-57e5-32bf-9b61-44bc15b05b9d",
      "content": {
        "id": "9e9aa5fe-57e5-32bf-9b61-44bc15b05b9d",
        "contentType": "STORY",
        "title": "Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study",
        "description": "",
        "summary": "Fulcrum Therapeutics, Inc. (NASDAQ:FULC) is one of the 12 best multibagger stocks to buy heading into 2026. Following encouraging updates from the ongoing Phase 1b PIONEER study evaluating pociredir in sickle cell disease, analyst sentiment around Fulcrum Therapeutics, Inc. (NASDAQ:FULC) appears to be growing. As of December 18, 2025, 80% of analysts are bullish on […]",
        "pubDate": "2025-12-21T12:31:23Z",
        "displayTime": "2025-12-21T12:31:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/ac222f5096100e036cfe3dc89568ace8",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LU2FLfKhubXe0kD.EJyMWg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/ac222f5096100e036cfe3dc89568ace8.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nSb6YNh4YtBqRwspkeN6dw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/ac222f5096100e036cfe3dc89568ace8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bullish-analyst-sentiment-fulcrum-therapeutics-123123949.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bullish-analyst-sentiment-fulcrum-therapeutics-123123949.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "FULC"
            },
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-21T12:31:20+00:00",
    "headline": "High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin",
    "summary": "With strong 1-year returns and upside potential, Palvella Therapeutics, Inc. (NASDAQ:PVLA) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026. On December 16, 2025, analyst confidence in Palvella Therapeutics, Inc. (NASDAQ:PVLA) was seen rising, as the company announced encouraging Phase 2 data for QTORIN rapamycin in cutaneous […]",
    "url": "https://finance.yahoo.com/news/high-analyst-confidence-palvella-therapeutics-123120180.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "94f40c28-761e-3f42-ae01-05fe60454ee9",
      "content": {
        "id": "94f40c28-761e-3f42-ae01-05fe60454ee9",
        "contentType": "STORY",
        "title": "High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin",
        "description": "",
        "summary": "With strong 1-year returns and upside potential, Palvella Therapeutics, Inc. (NASDAQ:PVLA) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026. On December 16, 2025, analyst confidence in Palvella Therapeutics, Inc. (NASDAQ:PVLA) was seen rising, as the company announced encouraging Phase 2 data for QTORIN rapamycin in cutaneous […]",
        "pubDate": "2025-12-21T12:31:20Z",
        "displayTime": "2025-12-21T12:31:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/6a3eb9e1b9760b4bed78b16d1253664c",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BmBW9k2APq04bcY0cbi9DA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/6a3eb9e1b9760b4bed78b16d1253664c.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/az9U5V8Z7oN9MQphgaNFnA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/6a3eb9e1b9760b4bed78b16d1253664c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/high-analyst-confidence-palvella-therapeutics-123120180.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/high-analyst-confidence-palvella-therapeutics-123120180.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PVLA"
            },
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-21T13:07:57+00:00",
    "headline": "How The Latest Analyst Reset Is Shaping MTN Group’s Long Term Story",
    "summary": "MTN Group’s latest valuation update leaves its fair value estimate and discount rate effectively unchanged, signaling that analysts see no need to rewrite the long term story despite recent market noise. The minimal tweaks to growth assumptions are best read as a technical rebasing rather than a fundamental reset, suggesting the market may already be pricing in a slower, more complex recovery path. Read on to see how these seemingly small adjustments can shape the evolving narrative around...",
    "url": "https://finance.yahoo.com/news/latest-analyst-reset-shaping-mtn-130757108.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "c9ae8a24-37d3-3a2d-b177-39f2b55e2f8e",
      "content": {
        "id": "c9ae8a24-37d3-3a2d-b177-39f2b55e2f8e",
        "contentType": "STORY",
        "title": "How The Latest Analyst Reset Is Shaping MTN Group’s Long Term Story",
        "description": "",
        "summary": "MTN Group’s latest valuation update leaves its fair value estimate and discount rate effectively unchanged, signaling that analysts see no need to rewrite the long term story despite recent market noise. The minimal tweaks to growth assumptions are best read as a technical rebasing rather than a fundamental reset, suggesting the market may already be pricing in a slower, more complex recovery path. Read on to see how these seemingly small adjustments can shape the evolving narrative around...",
        "pubDate": "2025-12-21T13:07:57Z",
        "displayTime": "2025-12-21T13:07:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/6008364ab7a4bfa5cc53e4098a01b3b0",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/54ngJ9HCWnF97pxPsQiK3w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/6008364ab7a4bfa5cc53e4098a01b3b0.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/217hUOMFIAE4nyOrvGlqmA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/6008364ab7a4bfa5cc53e4098a01b3b0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/latest-analyst-reset-shaping-mtn-130757108.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/latest-analyst-reset-shaping-mtn-130757108.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTNOF"
            },
            {
              "symbol": "MTN"
            },
            {
              "symbol": "TFC"
            },
            {
              "symbol": "MT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]